Blincyto, the first and only FDA-approved Bispecific CD19-directed CD3 T-cell Engager

  • Speaker: Dr. Stefan Faderl, chief Leukemia Division of Hackensack Medical Center in New Jersey
  • 6pm, April 1, 2015
  • Mahogany, 3241 West Memorial Road, OKC (405-748-5859)
  • RSVPs can be sent to Ruth Kostur at 503-412-9999 or
  • Click Here for more information

No comments have been posted yet.